Conexiant’s news site is now MDSpire News. Learn more
Advertisement
SRSF1 Gene Delivery Extends Lifespan in Aged Mice
An RNA sequencing and machine learning screening platform identified an RNA-processing factor that reduced markers of cellular aging without erasing cell identity
Clinical Scorecard: SRSF1 Gene Delivery Extends Lifespan in Aged Mice
At a Glance
Category
Detail
Condition
Age-related cellular decline and frailty
Key Mechanisms
SRSF1 encodes an RNA splicing factor. In human fibroblasts, its overexpression was associated with reduced cellular senescence, inflammatory signaling, and proteostatic stress, and restoration of DNA repair programs; the mechanisms linking RNA processing to these effects remain under investigation.
Target Population
Preclinical study of human fibroblasts and aged female mice
Care Setting
Preclinical research; findings have not established a clinical treatment for aging or frailty.
Key Highlights
A machine learning model trained on gene-expression data from 464 human fibroblast samples was used to screen candidate genes.
SRSF1 overexpression produced the most consistent reduction in predicted transcriptomic age among the screened genes.
In aged female mice, inducible SRSF1 delivery increased median lifespan from 778 to 886 days.
Treatment reduced the rate of frailty accumulation by approximately 44% and delayed sustained frailty onset by 123 days.
The study was preclinical and conducted in a small mouse cohort; expression timing and level affected observed outcomes.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Excessive expression of Yamanaka reprogramming factors can return mature cells to a pluripotent state and increase tumor risk.
Constitutive SRSF1 overexpression did not improve skin repair or muscle regeneration, despite producing higher SRSF1 levels.
Patient & Prescribing Data
No human patients were treated. Experiments included human fibroblasts and aged female mice.
An inducible SRSF1 construct was delivered to aged mice using an adeno-associated viral vector that primarily targeted the liver. The findings are preclinical and do not establish a human dose, safety profile, or prescribing recommendation.
Clinical Best Practices
Interpret the lifespan and frailty findings as results from a small preclinical mouse cohort, not as evidence of efficacy in humans.
Distinguish inducible SRSF1 expression from constitutive overexpression; the article reports different outcomes.
The researchers are still investigating how SRSF1-related RNA-processing changes produce the observed effects.
